Transmembrane chemokines: Versatile ‘special agents’ in vascular inflammation

Summary

Within the chemokine family of small chemotactic polypeptides CX3CL1 (fractalkine) and CXCL16 (SR-PSOX) are exceptional in that they are synthesized as transmembrane molecules and can be cleaved from the cell surface to produce a soluble chemoattractant. As transmembrane molecules on the surface of endothelial cells, CX3CL1 and CXCL16 can interact with their receptors CX3CR1 and CXCR6, respectively, which are expressed on leukocyte subtypes.This interaction leads to cell-cell adhesion that is resistant to shear forces. Transmembrane CX3CL1 and CXCL16 are constitutively shed from the cell surface by the activity of a disintegrin and metalloproteinase (ADAM) 10, and cleavage can be rapidly enhanced by activation of the closely related enzyme ADAM17. This cleavage leads to the downregulation of adhesive properties and may even result in the detachment of bound cells. Functionally, both chemokines appear to exert homeostatic and inflammatory activities. Basal expression of CX3CL1 or CXCL16 may be relevant for positioning and survival of tissue-homing leukocytes. Upregulated expression is found under inflammatory conditions such as atherosclerosis where CXCL16 may have a dual function by acting as an adhesion molecule and by promoting uptake of oxidized LDL as a scavenger receptor. Accumulating evidence from knockout mice and genetic polymorphisms in humans points towards a differential contribution of CX3CL1 and CXCL16 in atherosclerosis, where shedding may serve to further regulate their biological functions. Small molecules that block either the receptors or the shedding enzymes of transmembrane chemokines need to be tested in animal models of vascular inflammation.

Keywords

Chemokines - adhesion - metalloproteinases - shedding - atherosclerosis

• References

• 1 Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
• 2 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
• 3 Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928.
• 4 Colditz IG, Schneider MA, Pruenster M. et al. Chemokines at large: In-vivo mechanisms of their transport, presentation and clearance. Thromb Haemost 2007; 97: 688-693.
• 5 Weber C. Novel mechanistic concepts for the control of leukocyte transmigration: specialization of integrins, chemokines, and junctional molecules. J Mol Med 2003; 81: 4-19.
• 6 Weber C, Schober A, Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004; 24: 1997-2008.
• 7 Umehara H, Bloom ET, Okazaki T. et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34-40.
• 8 Bazan JF, Bacon KB, Hardiman G. et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-644.
• 9 Matloubian M, David A, Engel S. et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol 2000; 01: 298-304.
• 10 Wilbanks A, Zondlo SC, Murphy K. et al. Expression cloning of the STRL33/BONZO/TYMSTRligand reveals elements of CC, CXC, and CX3C chemokines. J Immunol 2001; 166: 5145-5154.
• 11 Shimaoka T, Kume N, Minami M. et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem 2000; 275: 40663-40666.
• 12 Pan Y, Lloyd C, Zhou H. et al. Neurotactin, a membrane- anchored chemokine upregulated in brain inflammation. Nature 1997; 387: 611-617.
• 13 Hoover DM, Mizoue LS, Handel TM. et al. The crystal structure of the chemokine domain of fractalkine shows a novel quaternary arrangement. J Biol Chem 2000; 275: 23187-23193.
• 14 Mizoue LS, Bazan JF, Johnson EC. et al. Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. Biochemistry 1999; 38: 1402-1414.
• 15 Haskell CA, Cleary MD, Charo IF. Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem 2000; 275: 34183-34189.
• 16 Nomiyama H, Imai T, Kusuda J. et al. Human chemokines fractalkine (SCYD1), MDC (SCYA22) and TARC (SCYA17) are clustered on chromosome 16q13. Cytogenet Cell Genet 1998; 81: 10-11.
• 17 Weber C, Koenen RR. Fine-tuning leukocyte responses: towards a chemokine 'interactome'. Trends Immunol 2006; 27: 268-273.
• 18 Liu GY, Kulasingam V, Alexander RT. et al. Recycling of the membrane-anchored chemokine, CX3CL1. J Biol Chem 2005; 280: 19858-19866.
• 19 Chapman GA, Moores K, Harrison D. et al. Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 2000; 20: RC87
• 20 Ludwig A, Berkhout T, Moores K. et al. Fractalkine is expressed by smooth muscle cells in response to IFNgamma and TNF-alpha and is modulated by metalloproteinase activity. J Immunol 2002; 168: 604-612.
• 21 Gough PJ, Garton KJ, Wille PT. et al. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol 2004; 172: 3678-3685.
• 22 Hundhausen C, Misztela D, Berkhout TA. et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003; 102: 1186-1195.
• 23 Garton KJ, Gough PJ, Blobel CP. et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001; 276: 37993-38001.
• 24 Tsou CL, Haskell CA, Charo IF. Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem 2001; 276: 44622-44626.
• 25 Abel S, Hundhausen C, Mentlein R. et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol 2004; 172: 6362-6372.
• 26 Reiss K, Ludwig A, Saftig P. Breaking up the tie: Disintegrin-like metalloproteinases as regulators of cell migration in inflammation and invasion. Pharmacol Ther 2006; 111: 985-1006.
• 27 Damas JK, Boullier A, Waehre T. et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005; 25: 2567-2572.
• 28 Rimaniol AC, Till SJ, Garcia G. et al. The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol 2003; 112: 1139-1146.
• 29 Kastenbauer S, Koedel U, Wick M. et al. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system. J Neuroimmunol 2003; 137: 210-217.
• 30 Yajima N, Kasama T, Isozaki T. et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005; 52: 1670-1675.
• 31 Ruth JH, Haas CS, Park CC. et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent upon the MAPK pathway. Arthritis Rheum 2006; 54: 765-778.
• 32 Ruth JH, Volin MV, Haines GK III. et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001; 44: 1568-1581.
• 33 Lucas AD, Bursill C, Guzik TJ. et al. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation 2003; 108: 2498-2504.
• 34 Imaizumi T, Yoshida H, Satoh K. Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 2004; 11: 15-21.
• 35 Garcia GE, Xia Y, Chen S. et al. NF-kappaB-dependent fractalkine induction in rat aortic endothelial cells stimulated by IL-1beta, TNF-alpha, and LPS. J Leukoc Biol 2000; 67: 577-584.
• 36 Fraticelli P, Sironi M, Bianchi G. et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001; 107: 1173-1181.
• 37 Imaizumi T, Matsumiya T, Fujimoto K. et al. Interferon- gamma stimulates the expression of CX3CL1/fractalkine in cultured human endothelial cells. Tohoku J Exp Med 2000; 192: 127-139.
• 38 Matsumiya T, Imaizumi T, Fujimoto K. et al. Soluble interleukin-6 receptor alpha inhibits the cytokine- Induced fractalkine/CX3CL1 expression in human vascular endothelial cells in culture. Exp Cell Res 2001; 269: 35-41.
• 39 Yoshida H, Imaizumi T, Fujimoto K. et al. Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. Neurosci Lett 2001; 303: 132-136.
• 40 Wagsater D, Olofsson PS, Norgren L. et al. The chemokine and scavenger receptor CXCL16/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Biochem Biophys Res Commun 2004; 325: 1187-1193.
• 41 Chandrasekar B, Mummidi S, Valente AJ. et al. The pro-atherogenic cytokine interleukin-18 induces CXCL16 expression in rat aortic smooth muscle cells via MyD88, interleukin-1 receptor-associated kinase, tumor necrosis factor receptor-associated factor 6, c-Src, phosphatidylinositol 3-kinase, Akt, c-Jun N-terminal kinase, and activator protein-1 signaling. J Biol Chem 2005; 280: 26263-26277.
• 42 Greaves DR, Hakkinen T, Lucas AD. et al. Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activationregulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001; 21: 923-929.
• 43 Minami M, Kume N, Shimaoka T. et al. Expression of SR-PSOX, a novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001; 21: 1796-1800.
• 44 Wuttge DM, Zhou X, Sheikine Y. et al. CXCL16/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004; 24: 750-755.
• 45 Lucas AD, Chadwick N, Warren BF. et al. The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001; 158: 855-866.
• 46 Ludwig A, Schulte A, Schnack C. et al. Enhanced expression and shedding of the transmembrane chemokine CXCL16 by reactive astrocytes and glioma cells. J Neurochem 2005; 93: 1293-1303.
• 47 Scholz F, Schulte A, Adamski F. et al. Constitutive expression and regulated release of the transmembrane chemokine CXCL16 in human and murine skin. J Invest Dermatol. 2007 in press
• 48 Combadiere C, Salzwedel K, Smith ED. et al. Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998; 273: 23799-23804.
• 49 Imai T, Hieshima K, Haskell C. et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-530.
• 50 Schafer A, Schulz C, Eigenthaler M. et al. Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103: 407-412.
• 51 Schafer A, Schulz C, Fraccarollo D. et al. The CX3C chemokine fractalkine induces vascular dysfunction by generation of superoxide anions. Arterioscler Thromb Vasc Biol 2007; 27: 55-62.
• 52 Nishimura M, Umehara H, Nakayama T. et al. Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002; 168: 6173-6180.
• 53 Jung S, Aliberti J, Graemmel P. et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol 2000; 20: 4106-4114.
• 54 Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
• 55 Ancuta P, Rao R, Moses A. et al. Fractalkine preferentially mediates arrest and migration of CD16+ monocytes. J Exp Med 2003; 197: 1701-1707.
• 56 Barlic J, Sechler JM, Murphy PM. IL-15 and IL-2 oppositely regulate expression of the chemokine receptor CX3CR1. Blood 2003; 102: 3494-3503.
• 57 Liao F, Alkhatib G, Peden KW. et al. STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997; 185: 2015-2023.
• 58 Deng HK, Unutmaz D, Kewalramani VN. et al. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature 1997; 388: 296-300.
• 59 Unutmaz D, Xiang W, Sunshine MJ. et al. The primate lentiviral receptor Bonzo/STRL33 is coordinately regulated with CCR5 and its expression pattern is conserved between human and mouse. J Immunol 2000; 165: 3284-3292.
• 60 Geissmann F, Cameron TO, Sidobre S. et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol 2005; 03: e113
• 61 Kim CH, Kunkel EJ, Boisvert J. et al. Bonzo/ CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest 2001; 107: 595-601.
• 62 Harrison JK, Jiang Y, Chen S. et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 1998; 95: 10896-10901.
• 63 Zhuge X, Murayama T, Arai H. et al. CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. Biochem Biophys Res Commun 2005; 331: 1295-1300.
• 64 Gevrey JC, Isaac BM, Cox D. Syk is required for monocyte/macrophage chemotaxis to CX3CL1 (Fractalkine). J Immunol 2005; 175: 3737-3745.
• 65 Cambien B, Pomeranz M, Schmid-Antomarchi H. et al. Signal transduction pathways involved in soluble fractalkine-induced monocytic cell adhesion. Blood 2001; 97: 2031-2037.
• 66 Vitale S, Schmid-Alliana A, Breuil V. et al. Soluble fractalkine prevents monocyte chemoattractant protein- 1-induced monocyte migration via inhibition of stress-activated protein kinase 2/p38 and matrix metalloproteinase activities. J Immunol 2004; 172: 585-592.
• 67 Umehara H, Goda S, Imai T. et al. Fractalkine, a CX3C-chemokine, functions predominantly as an adhesion molecule in monocytic cell line THP-1. Immunol Cell Biol 2001; 79: 298-302.
• 68 Nakayama T, Hieshima K, Izawa D. et al. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003; 170: 1136-1140.
• 69 Johnston B, Kim CH, Soler D. et al. Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J Immunol 2003; 171: 2960-2969.
• 70 Shimaoka T, Nakayama T, Fukumoto N. et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol 2004; 75: 267-274.
• 71 Fong AM, Robinson LA, Steeber DA. et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998; 188: 1413-1419.
• 72 Zernecke A, Weber KS, Erwig LP. et al. Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. J Immunol 2001; 166: 5755-5762.
• 73 Goda S, Imai T, Yoshie O. et al. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 2000; 164: 4313-4320.
• 74 Kerfoot SM, Lord SE, Bell RB. et al. Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions; a mechanism for selective monocyte recruitment. Eur J Immunol 2003; 33: 729-739.
• 75 Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem 2004; 279: 3188-3196.
• 76 Lee SJ, Namkoong S, Kim YM. et al. Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ ERK- and PI3K/Akt/eNOS-dependent signal pathways. Am J Physiol Heart Circ Physiol 2006; 291: H2836-H2846.
• 77 Chandrasekar B, Mummidi S, Perla RP. et al. Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochem J 2003; 373: 547-558.
• 78 Yoneda O, Imai T, Goda S. et al. Fractalkine-mediated endothelial cell injury by NK cells. J Immunol 2000; 164: 4055-4062.
• 79 Yoneda O, Imai T, Nishimura M. et al. Membranebound form of fractalkine induces IFN-gamma production by NK cells. Eur J Immunol 2003; 33: 53-58.
• 80 Gursel M, Gursel I, Mostowski HS. et al. CXCL16 influences the nature and specificity of CpG-induced immune activation. J Immunol 2006; 177: 1575-1580.
• 81 Shimaoka T, Nakayama T, Kume N. et al. Cutting edge: SR-PSOX/CXC chemokine ligand 16 mediates bacterial phagocytosis by APCs through its chemokine domain. J Immunol 2003; 171: 1647-1651.
• 82 Krijgsveld J, Zaat SA, Meeldijk J. et al. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 2000; 275: 20374-20381.
• 83 Hulshof S, van Haastert ES, Kuipers HF. et al. CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis. J Neuropathol Exp Neurol 2003; 62: 899-907.
• 84 Meucci O, Fatatis A, Simen AA. et al. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. Proc Natl Acad Sci USA 2000; 97: 8075-8080.
• 85 Johnston IN, Milligan ED, Wieseler-Frank J. et al. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004; 24: 7353-7365.
• 86 Milligan ED, Zapata V, Chacur M. et al. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci 2004; 20: 2294-2302.
• 87 Niess JH, Brand S, Gu X. et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005; 307: 254-258.
• 88 Hase K, Murakami T, Takatsu H. et al. The membrane- bound chemokine CXCL16 expressed on follicle- associated epithelium and M cells mediates lympho- epithelial interaction in GALT. J Immunol 2006; 176: 43-51.
• 89 Wong BW, Wong D, McManus BM. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002; 11: 332-338.
• 90 Lesnik P, Haskell CA, Charo IF. Decreased atherosclerosis in CX3CR1^-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003; 111: 333-340.
• 91 Combadiere C, Potteaux S, Gao JL. et al. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation 2003; 107: 1009-1016.
• 92 Cook DN, Chen SC, Sullivan LM. et al. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol 2001; 21: 3159-3165.
• 93 Teupser D, Pavlides S, Tan M. et al. Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci USA 2004; 101: 17795-17800.
• 94 Boring L, Gosling J, Cleary M. et al. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897.
• 95 Tacke F, Alvarez D, Kaplan TJ. et al. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117: 185-194.
• 96 Schober A, Zernecke A, Liehn EA. et al. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circ Res 2004; 95: 1125-1133.
• 97 Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost 2007; 97: 730-737.
• 98 Liu P, Patil S, Rojas M. et al. CX3CR1 deficiency confers protection from intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 2006; 26: 2056-2062.
• 99 Furuichi K, Gao JL, Murphy PM. Chemokine receptor CX3CR1 regulates renal interstitial fibrosis after ischemia-reperfusion injury. Am J Pathol 2006; 169: 372-387.
• 100 Soriano SG, Amaravadi LS, Wang YF. et al. Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 2002; 125: 59-65.
• 101 Faure S, Meyer L, Costagliola D. et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000; 287: 2274-2277.
• 102 McDermott DH, Halcox JP, Schenke WH. et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89: 401-407.
• 103 Moatti D, Faure S, Fumeron F. et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97: 1925-1928.
• 104 Daoudi M, Lavergne E, Garin A. et al. Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1. J Biol Chem 2004; 279: 19649-19657.
• 105 McDermott DH, Fong AM, Yang Q. et al. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 2003; 111: 1241-1250.
• 106 Norata GD, Garlaschelli K, Ongari M. et al. Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke 2006; 37: 1558-1561.
• 107 Ghilardi G, Biondi ML, Turri O. et al. Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor. Stroke 2004; 35: 1276-1279.
• 108 Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation 2006; 114: 583-590.
• 109 Janes PW, Saha N, Barton WA. et al. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 2005; 123: 291-304.
• 110 Cardona AE, Pioro EP, Sasse ME. et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 09: 917-924.
• 111 Inoue A, Hasegawa H, Kohno M. et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/ lpr mice. Arthritis Rheum 2005; 52: 1522-1533.
• 112 Ludwig A, Hundhausen C, Lambert MH. et al. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb Chem High Throughput Screen 2005; 08: 161-171.
• 113 Black RA, Rauch CT, Kozlosky CJ. et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997; 385: 729-733.
• 114 Althoff K, Reddy P, Voltz N. et al. Shedding of interleukin- 6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 2000; 267: 2624-2631.
• 115 Budagian V, Bulanova E, Orinska Z. et al. Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17). J Biol Chem 2004; 279: 40368-40375.
• 116 Peschon JJ, Slack JL, Reddy P. et al. An essential role for ectodomain shedding in mammalian development. Science 1998; 282: 1281-1284.
• 117 Stoeck A, Keller S, Riedle S. et al. A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochem J 2006; 393: 609-618.
• 118 Maretzky T, Reiss K, Ludwig A. et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci USA 2005; 102: 9182-9187.
• 119 Reiss K, Maretzky T, Ludwig A. et al. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J 2005; 24: 742-752.
• 120 Garton KJ, Gough PJ, Philalay J. et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alphaconverting enzyme (ADAM 17). J Biol Chem 2003; 278: 37459-37464.
• 121 Garton KJ, Gough PJ, Raines EW. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. J Leukoc Biol 2006; 79: 1105-1116.
• 122 Haskell CA, Hancock WW, Salant DJ. et al. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 2001; 108: 679-688.
• 123 Huang D, Shi FD, Jung S. et al. The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J 2006; 20: 896-905.